| Study | Men/total | Age | Diagnostic criteria | Therapy duration | Interventions | Response definition | Method | Jadad scores | Dropout rate | T | C |
| Guo et al., 2012 | T 29/50 C 26/50 | T 40.8 ± 13.2 C 43.2 ± 14.3 | CCMD-3 HAMA ≥ 14 | 6 w | JWZX 18 g/d | Buspirone 15–60 mg/d | HAMA, TESS, response rate | Randomization, blinding of experimenter, participants, and assessors (placebo) | 3 | NR |
| Liang, 2012 | T 18/40 C 19/40 | T 40.5 ± 11.4 C 41.0 ± 10.9 | CCMD-3 HAMA > 14 | 6 w | JWZX 18 g/d | Sertraline 50–100 mg/d | HAMA, TESS, response rate | Randomization | 1 | NR |
| Liang, 2014 | T 22/54 C 20/53 | T 36.5 ± 4.3 C 35.6 ± 4.2 | CCMD-3 HAMA ≥ 14 | 6 w | JWZX 18 g/d | Paroxetine 10–40 mg/d | HAMA, TESS, response rate | Randomization (random digit table), dropouts | 3 | T 2 C 3 |
| Liu, 2013 | T 13/32 C 15/35 | T 37.7 ± 8.6 C 38.7 ± 9.1 | ICD-10 HAMA ≥ 14 | 6 w | JWZX 18 g/d | Buspirone 15–30 mg/d | HAMA, TESS, response rate | Randomization, dropouts | 2 | T 5 C 6 |
| Wang et al., 2013 | T 140/336 C 41/111 | T 42 ± 14 C 43 ± 13 | CCMD-3 HAMA ≥ 14 | 4 w | JWZX 24.1 ± 4.0 g/d | Buspirone 24.5 ± 4.3 mg/d | HAMA, TESS, response rate | Randomization (random digit table), dropouts, blinding of experimenter, participants, and assessors (placebo) | 5 | T 22/337 C 6/111 |
| Wu et al., 2012 | T 12/30 C 14/30 | T 31.5 ± 15.5 C 33.5 ± 13.2 | CCMD-3 HAMA ≥ 14 SAS ≥ 50 | 6 w | JWZX 18 g/d | Tandospirone 30 mg/d | HAMA, SAS, TESS response rate | Randomization, blinding of assessors | 1 | NR |
| Wu and Wang, 2012 | 32/68 | 34.4 ± 4.9 | ICD-10 HAMA ≥ 14 SAS ≥ 50 | 8 w | JWZX 18 g/d | Sertraline 50 mg/d | HAMA, TESS | Randomization | 1 | NR |
| Yang et al., 2013 | T 14/36 C 13/36 | T 33.5 ± 11.8 C 32.5 ± 12.1 | CCMD-3 HAMA ≥ 14 | 8 w | JWZX 18 g/d | Tandospirone 15–60 mg/d | HAMA, TESS, response rate | Randomization | 1 | NR |
| Zhang et al., 2012a | T 22/40 C 21/40 | T 42.2 ± 15.5 C 42.7 ± 15.0 | CCMD-3 | 6 w | JWZX 18 g/d | Buspirone 15–60 mg/d | HAMA, TESS, response rate | Randomization, blinding of assessors | 1 | NR |
| Zhang et al., 2012b | T 14/30 C 15/30 | T 38.4 ± 13.7 C 38.9 ± 12.9 | CCMD-3 HAMA ≥ 14 | 6 w | JWZX 18 g/d | Paroxetine 20 mg/d | HAMA, CGI, response rate | Randomization, dropouts, blinding of assessors | 2 | T 2 C 2 |
| Pan et al., 2016 | T 12/30 C 15/30 | T 36 ± 7.1 C 39.1 ± 9.6 | CCMD-3 | 4 W | JWZX 18 g/d | Tandospirone 15–30 mg/d | HAMA, response rate | Randomization, blinding of assessors | 3 | NR |
| Ren et al., 2015 | T 12/36 C 11/36 | T 34.6 ± 15.2 C 35.2 ± 13.9 | CCMD-3 | 6 W | JWZX 18 g/d | Paroxetine 10–40 mg/d | HAMA, TESS, response rate | Randomization, dropouts | 4 | T 3/36 C 4/36 |
| Ren and Hu, 2015 | NR | T 43.2 ± 6.7 C 42.4 ± 9.3 | CCMD-3 | 6 W | JWZX 18 g/d | Escitalopram 5–15 mg/d | HAMA, response rate | Randomization | 1 | NR |
| Ji, 2015 | T 19/32 C 18/33 | T 36.2 ± 11.4 C 38.5 ± 12.8 | CCMD-3 | 6 W | JWZX 18 g/d | Tandospirone 15–60 mg/d | HAMA, TESS, response rate | Randomization, dropouts | 1 | T 2 C 3 |
|
|